Answers are grounded in this paper and cite their sources.
Background: Carbapenem-resistant Gram-negative bacteria are an increasing concern in clinical practice, as treatment options for infections caused by these organisms are often limited. Rapid identification of carbapenemases can help clinicians make timely therapeutic decisions and implementation of appropriate infection-control measures. This study was undertaken to evaluate a rapid immunochromatographic lateral flow assay (LFA) for the detection of clinically important carbapenemases. Methods: Gram-negative bacilli from clinical isolates showing resistance to carbapenems were included in the study. Carbapenemase production was assessed using a commercially available rapid immunochromatographic lateral flow assay TRURAPID OKNVI RESIST-5 Test targeting the NDM, KPC, OXA-48, VIM and IMP-like carbapenemases. The results of the lateral flow assay were compared with those obtained by a reference molecular method for detection of carbapenemase genes. Results: During the study period of three months, 20 isolates of carbapenem resistant Gram negative bacilli were tested. Among these 8 isolates were co producers for OXA+NDM and 3 tested for NDM+VIM, three were positive for NDM+IMP, two were positive for NDM+OXA+VIM while two were OXA positive, one VIM positive, one NDM by PCR. The lateral flow assay detected all isolates with OXA and NDM. The results of isolates with co production of these enzymes were detected by the rapid kit. However none of the isolates with VIM was detected by the TRURAPID kit. Conclusion: The immunochromatographic lateral flow assay offers a practical ,simple, reliable rapid method for detecting important carbapenemases. in routine diagnostic laboratories, including settings where molecular testing is not readily available.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: